Orphan G-protein-coupled receptors: the next generation of drug targets?
- PMID: 9884064
- PMCID: PMC1565744
- DOI: 10.1038/sj.bjp.0702238
Orphan G-protein-coupled receptors: the next generation of drug targets?
Abstract
The pharmaceutical industry has readily embraced genomics to provide it with new targets for drug discovery. Large scale DNA sequencing has allowed the identification of a plethora of DNA sequences distantly related to known G protein-coupled receptors (GPCRs), a superfamily of receptors that have a proven history of being excellent therapeutic targets. In most cases the extent of sequence homology is insufficient to assign these 'orphan' receptors to a particular receptor subfamily. Consequently, reverse molecular pharmacological and functional genomic strategies are being employed to identify the activating ligands of the cloned receptors. Briefly, the reverse molecular pharmacological methodology includes cloning and expression of orphan GPCRs in mammalian cells and screening these cells for a functional response to cognate or surrogate agonists present in biological extract preparations, peptide libraries, and complex compound collections. The functional genomics approach involves the use of 'humanized yeast cells, where the yeast GPCR transduction system is engineered to permit functional expression and coupling of human GPCRs to the endogenous signalling machinery. Both systems provide an excellent platform for identifying novel receptor ligands. Once activating ligands are identified they can be used as pharmacological tools to explore receptor function and relationship to disease.
Similar articles
-
Orphan G protein-coupled receptors: from DNA to drug targets.Curr Opin Drug Discov Devel. 2001 Sep;4(5):535-47. Curr Opin Drug Discov Devel. 2001. PMID: 12825450 Review.
-
Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C).Genomics. 2000 Jul 1;67(1):8-18. doi: 10.1006/geno.2000.6226. Genomics. 2000. PMID: 10945465
-
Use of constitutive G protein-coupled receptor activity for drug discovery.Mol Pharmacol. 2000 Jan;57(1):125-34. Mol Pharmacol. 2000. PMID: 10617687
-
The G protein-coupled receptor repertoires of human and mouse.Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4903-8. doi: 10.1073/pnas.0230374100. Epub 2003 Apr 4. Proc Natl Acad Sci U S A. 2003. PMID: 12679517 Free PMC article.
-
Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits.Neurochem Int. 2007 Jul-Sep;51(2-4):140-64. doi: 10.1016/j.neuint.2007.06.006. Epub 2007 Jun 19. Neurochem Int. 2007. PMID: 17659814 Review.
Cited by
-
Ligand Fishing: A Remarkable Strategy for Discovering Bioactive Compounds from Complex Mixture of Natural Products.Molecules. 2016 Nov 11;21(11):1516. doi: 10.3390/molecules21111516. Molecules. 2016. PMID: 27845727 Free PMC article. Review.
-
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.Mol Endocrinol. 2014 Mar;28(3):281-94. doi: 10.1210/me.2013-1314. Epub 2014 Jan 16. Mol Endocrinol. 2014. PMID: 24433041 Free PMC article. Review.
-
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.CNS Drug Rev. 2005 Summer;11(2):97-112. doi: 10.1111/j.1527-3458.2005.tb00264.x. CNS Drug Rev. 2005. PMID: 16007234 Free PMC article. Review.
-
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling.Chem Commun (Camb). 2003 Dec 21;(24):2949-56. doi: 10.1039/b303439a. Chem Commun (Camb). 2003. PMID: 14703805 Free PMC article. Review.
-
Therapeutic potential of blockade of the urotensin II system in systemic hypertension.Curr Hypertens Rep. 2007 Mar;9(1):53-8. doi: 10.1007/s11906-007-0010-x. Curr Hypertens Rep. 2007. PMID: 17362672 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
